| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROHUMORAL CONTROL OF CARDIOVASCULAR FUNCTION
1Max Delbrück Center for Molecular Medicine, Berlin; 2Medical Faculty of the Charité, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany; 3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri; and 4Autonomic Dysfunction Service, Vanderbilt University, Nashville, Tennessee
Submitted 22 April 2005 ; accepted in final form 26 October 2005
The regulator of G protein signaling (RGS) 2, a GTPase-activating protein, is activated via the nitric oxide (NO)-cGMP pathway and thereby may influence blood pressure regulation. To test that notion, we measured mean arterial blood pressure (MAP) and heart rate (HR) with telemetry in N
-nitro-L-arginine methyl ester (L-NAME, 5 mg L-NAME/10 ml tap water)-treated RGS2-deficient (RGS2–/–) and RGS2-sufficient (RGS2+/+) mice and assessed autonomic function. Without L-NAME, RGS2–/– mice showed during day and night a similar increase of MAP compared with controls. L-NAME treatment increased MAP in both strains. nNOS is involved in this L-NAME-dependent blood pressure increase, since 7-nitroindazole increased MAP by 8 and 9 mmHg (P < 0.05) in both strains. The L-NAME-induced MAP increase of 14–15 mmHg during night was similar in both strains. However, the L-NAME-induced MAP increase during the day was smaller in RGS2–/– than in RGS2+/+ (11 ± 1 vs. 17 ± 2 mmHg; P < 0.05). Urinary norepinephrine and epinephrine excretion was higher in RGS2–/– than in RGS2+/+ mice. The MAP decrease after prazosin was more pronounced in L-NAME-RGS2–/–. HR variability parameters [root mean square of successive differences (RMSSD), low-frequency (LF) power, and high-frequency (HF) power] and baroreflex sensitivity were increased in RGS2–/–. Atropine and atropine plus metoprolol markedly reduced RMSSD, LF, and HF. Our data suggest an interaction between RGS2 and the NO-cGMP pathway. The blunted L-NAME response in RGS2–/– during the day suggests impaired NO signaling. The MAP increases during the active phase in RGS2–/– mice may be related to central sympathetic activation and increased vascular adrenergic responsiveness.
nitric oxide-guanosine 3'-cyclic monophosphate pathway; regulator of G protein signaling 2-deficient mice; blood pressure; autonomic nervous system; spectral analysis; baroreflex
This article has been cited by other articles:
|
|
 |
|
  S. Gu, S. Tirgari, and S. P. Heximer The RGS2 Gene Product from a Candidate Hypertension Allele Shows Decreased Plasma Membrane Association and Inhibition of Gq Mol. Pharmacol., April 1, 2008; 73(4): 1037 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Weber, D. Bernhard, R. Lukowski, P. Weinmeister, R. Worner, J. W. Wegener, N. Valtcheva, S. Feil, J. Schlossmann, F. Hofmann, et al. Rescue of cGMP Kinase I Knockout Mice by Smooth Muscle Specific Expression of Either Isozyme Circ. Res., November 26, 2007; 101(11): 1096 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Hercule, J. Tank, R. Plehm, M. Wellner, A. C. da Costa Goncalves, M. Gollasch, A. Diedrich, J. Jordan, F. C. Luft, and V. Gross Cardiovascular Control: Regulator of G protein signalling 2 ameliorates angiotensin II-induced hypertension in mice Exp Physiol, November 1, 2007; 92(6): 1014 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Fitzgerald, B. K. Kemp-Harper, H. C. Parkington, G. A. Head, and R. G. Evans Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarizing factor Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R707 - R713. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
